Severin Schwan, Roche CEO (Sebastien Bozon/AFP via Getty Images)

Up­dat­ed: Roche hits the brakes on Alzheimer's tri­als af­ter res­ur­rect­ed drug flunks PhI­II

Is it fi­nal­ly time for Roche to give up on gan­tenerum­ab?

The Swiss phar­ma gi­ant re­vealed that the an­ti-amy­loid drug has failed two Phase III tri­als in ear­ly Alzheimer’s dis­ease, the lat­est in a streak of neg­a­tive read­outs for gan­tenerum­ab. Not on­ly did it miss the pri­ma­ry end­points of slow­ing clin­i­cal de­cline, the lev­el of be­ta-amy­loid re­moval was al­so low­er than ex­pect­ed.

In the wake of the flop, Roche’s Genen­tech sub­sidiary is hit­ting the brakes on SKY­LINE, a sep­a­rate Phase III tri­al that kicked off in March.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.